Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.73 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.73 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.59 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648042 | 1.00 | HTR3A (0.73) | HTR3AHRH4HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL31691646 | 0.98 | HTR3A (0.71) | HTR3AHRH4HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL3776403 | 0.98 | HTR3A (0.71) | HTR3AHRH4HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL30824484 | 0.96 | HTR3A (0.73) | HTR3AHRH4HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL6770810 | 0.86 | CHRNB2 (0.60) | HTR3AHRH4HCRTR1HCRTR2HSD17B10 | |
| SCHEMBL3551319 | 0.86 | HTR3A (0.69) | HTR3AHRH4HCRTR1HCRTR2HCAR2 | |
| SCHEMBL29460463 | 0.84 | HTR3A (0.67) | HTR3AHRH4HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL2420211 | 0.84 | HTR3A (0.67) | HTR3AHRH4HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL603314 | 0.84 | HTR3A (1.00) | HTR3AHRH4HCRTR1HCRTR2HSD17B10 | |
| SCHEMBL1029333 | 0.84 | HTR3A (0.67) | HTR3AHRH4HCRTR1HCRTR2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121429-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | 아주대학교산학협력단 | 2023-06-29 | — | — | WO | disclosed |
| CN-104918941-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-09-16 | — | — | CN | disclosed |
| CN-101087778-A | Pyrrolidinyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors | PFIZER (US) | 2007-12-12 | — | — | CN | disclosed |
| EP-1838702-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Pfizer Products Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060183763-A1 | Novel pyrrolidyl derivatives of heteroaromatic compounds | PFIZER INC | 2006-08-17 | — | — | US | disclosed |
| WO-2006070284-A1 | PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183763-A1 | Novel pyrrolidyl derivatives of heteroaromatic compounds | PDE12, PDE4A, PDE7A | HTR3A 794/4885HRH4 2228/4885HCRTR1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.